Insulet (PODD)
Nasdaq Market Closed
Insulet Corporation is a medical technology company best known for Omnipod, its tubeless insulin delivery system for people with insulin-dependent diabetes. Founded in 2000, the company focuses on making continuous subcutaneous insulin infusion therapy simpler and less intrusive than traditional pump systems that rely on tubing. Omnipod uses a small disposable pod worn on the body to deliver insulin, with dosing controlled through a handheld device or compatible smartphone-based interface depending on the product version and market.
Insulet serves patients with type 1 diabetes and some insulin-requiring type 2 diabetes patients. Its products are designed to support daily diabetes management by reducing the burden of injections and offering more flexible insulin delivery. The company’s newer systems, including automated insulin delivery versions, can work with compatible continuous glucose monitoring technology to help adjust insulin dosing based on glucose trends. This places Insulet within the broader diabetes technology market alongside pump makers, CGM companies, and digital health platforms.
The company generates revenue primarily through recurring sales of disposable pods, creating a consumables-driven model tied to patient adoption and retention. Since Omnipod received US Food and Drug Administration clearance in 2005, the platform has expanded internationally and is used by hundreds of thousands of people worldwide. Insulet’s growth depends on continued product innovation, insurance coverage, physician adoption, manufacturing scale, and its ability to compete in a market shaped by rising diabetes prevalence and demand for less burdensome care.
Last updated
- Market Cap
- 9.93B
- P/E
- 32.78
- P/FCF
- 24.82
- P/S
- 3.42
- Enterprise Value
- 10.39B
- Sector
- Health Care
- Industry
- Surgical and Medical Instruments and Apparatus
- Address
- 100 NAGOG PARK, ACTON, MA, 01720
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GoHealth Inc. - GOCO
BVI Appoints Jim Hollingshead as President & Chief Executive Officer
Diabetes Care Devices Market Size Projects USD 76.44 Billion by 2034
Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer
Thermo Fisher (TMO) Beats on Q2 Earnings, Raises 2024 EPS View - Zacks Investment Research
ESLOY vs. PODD: Which Stock Is the Better Value Option?
Insulet's (PODD) Omnipod 5 Favored in Study for Type 2 Diabetes
Insulet (PODD) Unveils Key Achievements for the Omnipod 5 System
Here's Why Insulet (PODD) is a Strong Momentum Stock
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
Insulet (PODD) Q1 Earnings Top, 2024 Revenue View Raised
Here's What Key Metrics Tell Us About Insulet (PODD) Q1 Earnings
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Gear Up for Insulet (PODD) Q1 Earnings: Wall Street Estimates for Key Metrics
Insulet (PODD) Rises Higher Than Market: Key Facts
Why Insulet (PODD) is a Top Momentum Stock for the Long-Term
Insulet (PODD) Outperforms Broader Market: What You Need to Know
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Chemed (CHE) Lags Q1 Earnings Estimates, Reaffirms 2024 View
Charles River (CRL) to Report Q1 Earnings: Here's What to Expect
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 9.93B
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 10.39B
- P/E
P/E ratio compares a company's share price to its earnings per share.
- 32.78
- P/B
P/B ratio compares a company's share price to its book value per share.
- 7.62
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 3.42
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 17.26
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 3.58
- EPS
- 4.37
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- 24.82
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- 16.03
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- 399.9M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- 23.25%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- 10.14%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0.73
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 2.49
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 1.81
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.7
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 1.68M
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 143.3
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 761.7M | 783.8M | 706.3M | 649.1M | 569M |
| Gross profit | 529M | 568.6M | 510.1M | 452.2M | 409.1M |
| Operating income | 122.1M | 146.3M | 117.7M | 121.1M | 88.8M |
| EBITDA | 148.3M | 170.7M | 139.7M | 143.4M | 110.5M |
| Net income | 91.1M | 101.6M | 87.6M | 22.5M | 35.4M |
| Basic EPS | 1.3 | 1.44 | 1.24 | 0.32 | 0.5 |
| Diluted EPS | 1.3 | 1.43 | 1.24 | 0.32 | 0.5 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 2.99B | 3.19B | 3.03B | 3.47B | 3.52B |
| Total liabilities | 1.68B | 1.68B | 1.65B | 2.01B | 2.19B |
| Total equity | 1.3B | 1.52B | 1.38B | 1.46B | 1.33B |
| Cash & equivalents | 480.4M | 716.1M | 757.4M | 1.12B | 1.28B |
| Current assets | 1.71B | 1.91B | 1.86B | 2.28B | 2.33B |
| Current liabilities | 687.5M | 680.1M | 647.7M | 1.01B | 520.4M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | 113.8M | 183.3M | 125.7M | 196.5M | 63.9M |
| Investing cash flow | -27.8M | -152.7M | -31M | -23.2M | -15.7M |
| Financing cash flow | -319.8M | -72.7M | -457M | -343.6M | 277.7M |
| Change in cash | -235.7M | -41.4M | -364.1M | -161.5M | 329.7M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | SD — INSULET CORP | View Filing | |
| edgar index | 8-K — INSULET CORP | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — INSULET CORP | View Filing | |
| edgar index | 4 — INSULET CORP | View Filing | |
| edgar index | 4 — INSULET CORP | View Filing | |
| edgar index | 4 — INSULET CORP | View Filing | |
| edgar index | 4 — INSULET CORP | View Filing | |
| edgar index | 4 — INSULET CORP | View Filing | |
| edgar index | 4 — INSULET CORP | View Filing | |
| edgar index | 4 — INSULET CORP | View Filing | |
| edgar index | 4 — INSULET CORP | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — BORIO LUCIANA | View Filing | |
| form 4 | Form 4 — Frederick Wayne A.I. | View Filing | |
| form 4 | Form 4 — Hopfield Jessica | View Filing | |
| form 4 | Form 4 — Huffines Robert Luther | View Filing | |
| form 4 | Form 4 — MINOGUE MICHAEL R | View Filing | |
| form 4 | Form 4 — MINOGUE MICHAEL R | View Filing | |
| form 4 | Form 4 — Scannell Timothy J | View Filing | |
| form 4 | Form 4 — STONESIFER TIMOTHY C. | View Filing | |
| form 4 | Form 4 — WEATHERMAN ELIZABETH H | View Filing | |
| edgar index | 4 — INSULET CORP | View Filing | |
| edgar index | SCHEDULE 13G/A — INSULET CORP | View Filing | |
| form 4 | Form 4 — McEvoy Ashley | View Filing | |
| form 4 | Form 4 — McEvoy Ashley | View Filing | |
| edgar index | SCHEDULE 13G/A — INSULET CORP | View Filing | |
| edgar index | 8-K — INSULET CORP | View Filing | |
| edgar index | 10-Q — INSULET CORP | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — INSULET CORP | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | DEF 14A — INSULET CORP | View Filing | |
| edgar index | DEFA14A — INSULET CORP | View Filing | |
| edgar index | 4 — INSULET CORP | View Filing | |
| edgar index | 3 — INSULET CORP | View Filing | |
| edgar index | 4 — INSULET CORP | View Filing | |
| form 3 | Form 3 — Panos Michael | View Filing | |
| form 4 | Form 4 — Panos Michael | View Filing | |
| form 4 | Form 4 — Panos Michael | View Filing | |
| form 4 | Form 4 — Huffines Robert Luther | View Filing | |
| edgar index | SCHEDULE 13G/A — INSULET CORP | View Filing | |
| edgar index | 8-K — INSULET CORP | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — INSULET CORP | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — INSULET CORP | View Filing | |
| edgar index | 4 — INSULET CORP | View Filing | |
| edgar index | 4 — INSULET CORP | View Filing | |
| edgar index | 4 — INSULET CORP | View Filing | |
| edgar index | 4 — INSULET CORP | View Filing | |
| form 4 | Form 4 — Benjamin Eric | View Filing | |
| form 4 | Form 4 — Benjamin Eric | View Filing | |
| form 4 | Form 4 — Kapples John W. | View Filing | |
| form 4 | Form 4 — Kapples John W. | View Filing | |
| form 4 | Form 4 — Budden Lauren | View Filing | |
| form 4 | Form 4 — Budden Lauren | View Filing | |
| form 4 | Form 4 — Cousin Laetitia | View Filing | |
| form 4 | Form 4 — Cousin Laetitia | View Filing | |
| form 4 | Form 4 — Singh Prem | View Filing | |
| form 4 | Form 4 — Singh Prem | View Filing | |
| edgar index | 4 — INSULET CORP | View Filing | |
| edgar index | 4 — INSULET CORP | View Filing | |
| edgar index | 4 — INSULET CORP | View Filing | |
| edgar index | 4 — INSULET CORP | View Filing | |
| edgar index | 4 — INSULET CORP | View Filing | |
| edgar index | 4 — INSULET CORP | View Filing | |
| edgar index | 4 — INSULET CORP | View Filing | |
| edgar index | 4 — INSULET CORP | View Filing | |
| edgar index | 4 — INSULET CORP | View Filing | |
| form 4 | Form 4 — MINOGUE MICHAEL R | View Filing | |
| form 4 | Form 4 — MINOGUE MICHAEL R | View Filing | |
| form 4 | Form 4 — Benjamin Eric | View Filing | |
| form 4 | Form 4 — Kapples John W. | View Filing | |
| form 4 | Form 4 — Budden Lauren | View Filing |